Tetra Bio-Pharma Inc. TBPMQ

TBPMQ Company Overview

Tetra Bio-Pharma Inc. (traded in the U.S. over-the-counter market under the symbol TBPMQ during restructuring proceedings) is a Canadian biopharmaceutical company focused on cannabinoid-derived therapeutics and drug discovery. The company has operated primarily in the pharmaceutical and biotechnology industries, with an emphasis on developing prescription drug candidates derived from cannabinoids for indications including pain management, oncology-related supportive care, and inflammatory conditions. Its historical business model centered on advancing regulated cannabinoial pharmaceutical products through clinical development rather than participating primarily in the recreational cannabis market.

The company’s principal revenue strategy historically depended on clinical-stage asset development, licensing opportunities, strategic partnerships, and potential commercialization of cannabinoid-based therapeutics. Tetra Bio-Pharma became known for developing products such as PPP001 (QIXLEEF), an investigational inhaled cannabinoid therapy, along with additional cannabinoid formulations targeting chronic pain and palliative care. Founded in Canada during the expansion of the medical cannabis sector, the company evolved from a cannabis-focused healthcare platform into a clinical-stage biopharmaceutical developer seeking pharmaceutical regulatory approval pathways in North America and other international markets. Public disclosures and market reporting indicate the company later faced significant financial distress and restructuring activity; some operational details after restructuring announcements remain limited in public filings.